首页> 美国卫生研究院文献>Emerging Infectious Diseases >Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment Arkhangelsk Oblast Russia 2005–2010
【2h】

Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment Arkhangelsk Oblast Russia 2005–2010

机译:2005-2010年俄罗斯阿尔汉格尔斯克州在耐多药结核病治疗期间获得耐药的危险因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acquired resistance to antituberculosis drugs decreases effective treatment options and the likelihood of treatment success. We identified risk factors for acquisition of drug resistance during treatment for multidrug-resistant tuberculosis (MDR TB) and evaluated the effect on treatment outcomes. Data were collected prospectively from adults from Arkhangelsk Oblast, Russia, who had pulmonary MDR TB during 2005–2008. Acquisition of resistance to capreomycin and of extensively drug-resistant TB were more likely among patients who received <3 effective drugs than among patients who received >3 effective drugs (9.4% vs. 0% and 8.6% vs. 0.8%, respectively). Poor outcomes were more likely among patients with acquired capreomycin resistance (100% vs. 25.9%), acquired ofloxacin resistance (83.6% vs. 22.7%), or acquired extensive drug resistance (100% vs. 24.4%). To prevent acquired drug resistance and poor outcomes, baseline susceptibility to first- and second-line drugs should be determined quickly, and treatment should be adjusted to contain >3 effective drugs.
机译:获得的抗结核药物耐药性降低了有效的治疗选择和治疗成功的可能性。我们确定了耐多药结核病(MDR TB)治疗期间获得耐药性的危险因素,并评估了其对治疗结果的影响。前瞻性收集了来自俄罗斯阿尔汉格尔斯克州成年人的数据,该成年人在2005-2008年期间患有肺部耐多药结核病。接受<3种有效药物的患者比接受> 3种有效药物的患者更有可能获得对卡普霉素和广泛耐药结核的耐药性(分别为9.4%vs. 0%和8.6%vs. 0.8%)。获得性卡普霉素耐药性(100%vs. 25.9%),获得性氧氟沙星耐药性(83.6%vs. 22.7%)或获得广泛耐药性(100%vs. 24.4%)的患者预后较差。为防止获得性耐药和不良预后,应快速确定对一线和二线药物的基线敏感性,并应调整治疗以包含> 3种有效药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号